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Abstract
Craniosynostosis, the premature ossification of cranial sutures, is a developmental disorder of the skull vault, occurring in
approximately 1 in 2250 births. The causes are heterogeneous, with a monogenic basis identified in ∼25% of patients. Using
whole-genome sequencing, we identified a novel, de novo variant in BCL11B, c.7C>A, encoding an R3S substitution (p.R3S), in
a male patient with coronal suture synostosis. BCL11B is a transcription factor that interacts directly with the nucleosome
remodelling and deacetylation complex (NuRD) and polycomb-related complex 2 (PRC2) through the invariant proteins
RBBP4 and RBBP7. The p.R3S substitution occurs within a conserved amino-terminal motif (RRKQxxP) of BCL11B and
reduces interaction with both transcriptional complexes. Equilibrium binding studies and molecular dynamics simulations
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show that the p.R3S substitution disrupts ionic coordination between BCL11B and the RBBP4–MTA1 complex, a subassembly
of the NuRD complex, and increases the conformational flexibility of Arg-4, Lys-5 and Gln-6 of BCL11B. These alterations
collectively reduce the affinity of BCL11B p.R3S for the RBBP4–MTA1 complex by nearly an order of magnitude. We generated
a mouse model of the BCL11B p.R3S substitution using a CRISPR-Cas9-based approach, and we report herein that these mice
exhibit craniosynostosis of the coronal suture, as well as other cranial sutures. This finding provides strong evidence that
the BCL11B p.R3S substitution is causally associated with craniosynostosis and confirms an important role for BCL11B in the
maintenance of cranial suture patency.
Introduction
The flat bones of the mammalian skull and face develop by
direct intramembranous ossification of mesenchyme, which is
principally derived frommesoderm and neural crest cells (NCCs)
(1). Craniofacial sutures are fibrocellular structures that form at
the margins of developing bones and limit skull deformation
due to both tensile and compressive forces (2). Development and
maintenance of sutures is essential and precisely controlled to
match skull expansion with the rapid increase in brain size of
infants (3).
The major sutures of the skull vault include the metopic
and sagittal sutures that separate the paired frontal and parietal
bones, respectively, the coronal sutures that form between the
parietal and frontal bones and the lambdoid sutures between
the parietal and occipital bones. Suture formation,maintenance
and subsequent ossification, the latter of which typically begins
in the third decade of human life, require the exquisitely chore-
ographed balance of proliferation and differentiation of sutural
stem cells and their progeny including bone-forming cells local-
ized at the boundaries of sutures (4).
Craniosynostosis is the most clinically important develop-
mental disorder of the skull vault. Associations of this disorder
include restricted skull expansion, increased intracranial pres-
sure and craniofacial dysmorphologies, all of which negatively
impact respiration, sensory systems and cognition (5). Failure of
themechanisms that establish the suture or that are responsible
for maintaining sutural patency result in craniosynostosis (2).
To date a genetic cause has been identified in approximately
a quarter of craniosynostosis cases with important implica-
tions for counselling and management (6). Mutations have been
detected predominantly in the fibroblast growth factor receptors
(FGFR2 and FGFR3), TWIST1 and EFNB1 (7,8). More recently, the
use of high-throughput sequencing has implicated mutations in
many other genes in the aetiology of craniosynostosis, including
TCF12 (9), SMAD6 (10), ERF (11), CDC45 (12) and ZIC1 (13). These
findings indicate that the causes of craniosynostosis are het-
erogeneous and involve many different pathways. In addition,
craniosynostosis can be present as a consistent, although rare,
feature where mutations have a non-specific impact on osteo-
genesis, for example affecting osteoblast to osteoclast balance
or chromatin modification (8).
Heterozygous mutations in BCL11B have been linked to
human pathologies affecting the immune system, intellectual
impairment, developmental abnormalities, as well as dermal
and craniofacial defects (14,15). BCL11B plays an essential role
in the development of the immune (14,16–22), central nervous
(23–25) and cutaneous (26) systems and teeth (27,28). Disruption
of a single Bcl11b allele in mice results in synostoses within
the facial skeleton (29). Bcl11b−/− mice, as well as mice
lacking BCL11B in neural crest-derived cells (Bcl11bncc−/−),
exhibit abnormally small and misshapen heads, severe midface
hypoplasia andmalocclusion. Fusion ofmultiple facial sutures is
seen in these mice, including the internasal, naso-premaxillary,
interfrontal, premaxillary-maxillary and temporal sutures. Some
Bcl11b−/− skulls are characterized by a high degree of porosity,
mirroring observations in human patients with increased
intracranial pressure (29).
Bcl11b−/−, but not Bcl11bncc−/−, mice exhibit severe coronal
suture craniosynostosis, which initiates around embryonic day
(E) 16.5—E18.5 (29). BCL11B is expressed in the coronal suture
beginning at E14.5 and loss of BCL11B results in ectopic expres-
sion of both Runx2 and Fgfr2c within the sutural mesenchyme
at E16.5, together with concomitant downregulation of Twist1
expression and ossification of the suture (29). These findings
collectively suggest a role for BCL11B in maintaining sutural
patency in the mammalian craniofacial skeleton.
Here we describe identification of a patient with cran-
iosynostosis carrying a de novo point mutation in BCL11B and
report the generation of a mouse model that recapitulates the
human phenotype. The mutation results in a single amino acid
substitution, p.R3S, which severely compromises interaction of
BCL11B with transcriptional regulatory complexes containing
RBBP4 and RBBP7, but not other transcriptional complexes with
which BCL11B interacts. Our data demonstrate that the BCL11B
p.R3S substitution underlies craniosynostosis in this patient
and that interaction of BCL11B with transcriptional regulatory
complexes containing RBBP4/7 plays a key role in the ability of
BCL11B to suppress the gene expression program underpinning
osteogenic differentiation within mammalian cranial sutures.
Results
Clinical description
The index patient was a Caucasian male, delivered by vacuum
extraction at 39 weeks of gestation weighing 3390 g. He was the
first child of non-consanguineous, unaffected parents. The fam-
ily history was negative for craniosynostosis. Examined directly
after birth, he was noted to have flattening of the forehead and
supra-orbital rim on the right side.
Physical examination at 10 months of age revealed a frontal
plagiocephalic head shape, mild vertical orbital dystopia, a high
philtrum, a short nose and narrow eyebrows (Fig. 1A–C). The
skull circumference was 44 cm (−1.81 SD). Skull radiographs
and three-dimensional computed tomography (3D-CT) showed
synostosis of the right coronal suture and increased fingerprint-
ing (Fig. 1D). Skull radiographs 2 months later showed partial
synostosis of the left coronal suture (not shown). A fronto-
supraorbital remodelling was performed at the age of 1 year.
At the age of 5 years, the patient developed impaired vision.
Fundoscopy showed papilledema (1.5 dpt right eye and 2 dpt left
eye), and a CT scan showed reduced peripheral cerebrospinal
fluid spaces, consistent with increased intracranial pressure.
This was confirmed by direct measurement (20 mm Hg), and
a second fronto-supraorbital advancement was performed. A
nonverbal IQ exam, completed at the age of 6 years, indicated a
score of 107 (Snijders-Oomen Nonverbal Intelligence Test 2.5-7).
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Figure 1. Clinical features. (A–C) Pre-operative facial photographs and 3D-CT scan (D) at the age of 10 months. Right coronal synostosis is indicated by the arrow.
(E–G) Post-operative facial photographs at the age of 15 years. (H) 3D-CT and angiogram scan at the age of 12 years just prior to distraction. (I) DNA sequence analysis
of proband and parents showing a de novo C>A variant (red arrow) in BCL11B (c.7C>A). The box encloses the start codon. (J) Alignment of amino termini of BCL11B,
transcription factors harbouring related sequences and histone H3.
At the age of 11 years, an epileptic insult was observed.
Shortly after, vision again declined and fundoscopy showed
bilateral papilledema of 2 dpt, while intracranial pressure
measurements and imaging (3D-CT and magnetic resonance
imaging) were inconclusive. A fronto-orbital advancement and
occipital distraction were performed at the age of 12 years.
Distraction started after 2 days but was paused after 9 days due
to severe headaches. A CT angiogramwith 3D-CT reconstruction
showed traction on the sagittal sinus and formation of
collaterals suboccipitally (Fig. 1H). Distraction was restarted
resulting in improvement in vision. Distractors were removed
after a period of 4 months. Subsequently, the patient developed
normally (Fig. 1E–G) and attended a normal school without
additional help up to the age of 16 years.
Genetic analysis
Karyotyping was normal and FGFR1, FGFR2, FGFR3, TWIST1 and
ERFwere negative for mutations by dideoxy-sequencing.Whole-
genome sequencing (WGS) (30) of the parent–child trio was
performed, and the data were analysed following a de novo
diseasemodel, as described previously (31). Twohigh-confidence
de novo coding variantswere identified (SupplementaryMaterial,
Table S1); the top ranked of which was in BCL11B (c.7C>A,
encoding p.R3S). Sequence analysis confirmed that this was a
de novo variant (Fig. 1I). Furthermore, the c.7C>A variant was
not present in any database, including the Exome Aggregation
Consortium (ExAC) and the Genome Aggregation Database (gno-
mAD) covering more than 120000 exomes or genomes from
unrelated individuals. The BCL11B variant was thought to likely
be causally significant, as Bcl11b is expressed in cranial sutures
(29,32), and Bcl11b−/− mice exhibit craniofacial abnormalities,
including craniosynostosis (29). Furthermore, the p.R3S substi-
tution occurs within a conserved amino-terminal domain found
within a class of NuRD complex interacting transcription factors
(Fig. 1J). The second-ranked variant was a de novo missense
change in FERMT2. It was considered unlikely to provide a major
contribution to the phenotype (Supplementary Material, Table
S1). All other coding variants had a low minimal somatic score,
and therefore were unlikely to be real. No variants of interest
were detected under a recessive or X-linked inheritance hypoth-
esis (data not shown).
To assess the contribution of BCL11B variants to craniosynos-
tosis aetiology more generally, we interrogated existing exome
sequencing and WGS data (186 cases) and screened by targeted
resequencing a panel of 382 unrelated probands, all without a
genetic diagnosis. In addition,we analysed BCL11B exon 1,which
encodes the conserved amino-terminal region of the protein, by
dideoxy sequencing in a further 115 cases thatwere not included
in the resequencing cohort. Although we identified several rare
variants by resequencing (Supplementary Material, Table S2),
no plausible causative changes were identified, indicating that
mutations of BCL11B leading to craniosynostosis may be rare
and/or highly specific.
Effect of p.R3S substitution on interaction of BCL11B
with transcriptional regulatory complexes
Co-immunoprecipitation (co-IP) analyses were performed in
extracts of transiently transfected HEK293T cells to determine
if the p.R3S substitution altered the spectrum of selected
transcriptional regulatory complexes with which BCL11B
interacts. The mutant protein was well expressed and localized
in the nucleus in a manner that was indistinguishable from
wild-type protein (Fig. 2A). However, co-IP studies revealed that
the amino acid substitution abolished the ability of BCL11B to
interact with both the NuRD (compare lanes 4 and 6 of top panel
of Fig. 2B; MTA2 and HDAC2 were used as markers of the NuRD
complex) and PRC2 complexes (compare lanes 4 and 6 of the
middle panel of Fig. 2B; enhancer of zeste 2 [EZH2] was used
as a marker of PRC2). The patient-derived substitution did not
affect the ability of BCL11B to interact with SIRT1, a class III
histone deacetylase (compare lanes 4 and 6 of bottom panel of
Fig. 2B), with which BCL11B interacts directly (33). Interaction
of BCL11B with PRC2, which to our knowledge has not been
reported previously, was hypothesized due to the presence of
RBBP4 and RBBP7 in the PRC2 complex and is demonstrated
herein.
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Figure 2. BCL11B p.R3S substitution disrupts interactionwith NuRD and PRC2 complexes. (A) Immunocytochemistry of HEK293T cells expressing wild-type BCL11B (top)
and BCL11B p.R3S (bottom). Cells were stained with an anti-BCL11B monoclonal antibody and co-stained with DAPI to visualize nuclei. (B) Co-immunoprecipitation
studies. BCL11B and BCL11B p.R3S were immunoprecipitated with the anti-FLAG antibody from transiently transfected HEK293T cells, and the corresponding blot
was probed with antibodies to BCL11B (red), MTA2 (green), HDAC2 (green), EZH2 (green) and SIRT1 (green). Comparison of lanes 4 (wild-type protein) and 6 (p.R3S)
demonstrates that the patient-derived BCL11B mutant does not interact with the NuRD or PRC2 complexes, however, the p.R3S substitution did not alter interaction of
the protein with the class III histone deacetylase SIRT1 (33). (C) Schematic outlining BCL11B interaction with the NuRD and PRC2 complexes.
Interaction of BCL11B and BCL11B p.R3S with the
RBBP4–MTA1 complex
The amino terminus of the NuRD-associated transcription factor
FOG-1 shares a conserved sequence with BCL11B (RRKQxxP, see
Fig. 1J). We used the high-resolution structure of FOG-1 pep-
tide bound to RBBP4 (34) to construct a model of BCL11B and
BCL11B p.R3S peptides bound to the RBBP4–MTA1 complex (35).
The resulting model predicts that BCL11B binds to an elec-
tronegative surface on one face of RBBP4, principally via three
invariant electropositive residues within the conserved, amino-
terminal region of BCL11B. Of these, Arg-4 is bound within an
electronegative channel of RBBP4, while Arg-3 and Lys-5 interact
with clefts closer to the top surface of RBBP4 (Fig. 3A). Recent
reports of the crystal structure of BCL11A and SALL4 in com-
plex with RBBP4 described similar findings, as expected (36,37).
The p.R3S substitution removes one of these charged RBBP4-
coordinated residues and generates a novel potential site for
post-translational modification (PTM; e.g. phosphorylation or O-
glycosylation). To evaluate the consequences of this substitution
we used fluorescence anisotropy to measure the equilibrium
binding affinity of amino-terminal BCL11B peptides to RBBP4–
MTA1 complex in vitro. We also conducted molecular dynamics
(MD) simulations to gain further insight into this molecular
association.
Using fluorescein-conjugated wild-type and BCL11B p.R3S
peptides, we estimated equilibrium binding affinities from the
increase in anisotropy when titrated with unlabelled RBBP4–
MTA1 complex. At physiological ionic strength the p.R3S sub-
stitution decreased the affinity of the BCL11B amino-terminal
peptide by 8.7-fold, from 0.133±0.043 μM, found with the wild-
type Arg-3 peptide, to 1.16±0.28 μM for the mutant, Ser-3-
containing peptide (Fig. 3B).
We conducted MD simulations to assess the consequence
of the p.R3S substitution on potential conformational changes
in the amino-terminal tail of BCL11B. The resulting equilibrium
structures of wild-type BCL11B peptide (Fig. 4A) were similar to
the FOG-1-based model (Fig. 3A) and the BCL11A–RBBP4 struc-
ture (36),while the BCL11B p.R3S equilibrium structures revealed
a conformational change in the peptide backbone at the site of
mutation affecting the coordination of nearby residues (Fig. 4B).
The mutant Ser-3 side chain was uncoordinated to RBBP4 and
its ψ-bond rotational change oriented both itself and Ser-2 away
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Figure 3. Effect of the p.R3S substitution on interaction of BCL11Bwith RBBP4–MTA1. (A) Modelledwild-type (green) and p.R3Smutant (yellow) BCL11B peptides (residues
1–15) superimposed and bound to the electrostatic potential surface of the RBBP4–MTA1 complex is shown. The electrostatic potential was calculated with APBS (69)
and shown in shades of blue and red to represent positive and negative potential, respectively, and visualized with UCSF Chimera (70). (B) Binding of fluorescein-
labelled wild-type and BCL11B p.R3S amino-terminal peptides to RBBP4–MTA1 complex as monitored by fluorescence anisotropy. Steady-state fluorescence anisotropy
measurements of each peptide (12.5 nm) are shown with increasing concentration of unlabelled RBBP4–MTA1 complex. Fluorescence anisotropy was calculated using
Eq. 1 and fit to Eq. 2. The dissociation constants for wild-type and BCL11B p.R3S peptides were 0.133±0.043 μm and 1.16± 0.28 μm, respectively. Data are from replicate
independent experiments, and the error estimate is the 95% confidence interval.
Figure 4. Effect of BCL11B p.R3S substitution on complex bound conformation. RBBP4–MTA1 complex bound structure BCL11B structure of wild-type (A) and p.R3S
mutant (B) showing the conformation of representative equilibrium structures from MD simulations.
from the RBBP4 surface.Themutant backbone conformationwas
indistinguishable from wild type at nearby invariant residues
Arg-4, Lys-5 and Gln-6 (Figs 4B and 5A), however, the side chains
of these residues favoured alternative positions.While the wild-
type BCL11B peptide Arg-4 preferred the axial conformation,
deep in the RBBP4 binding site as observed in other amino-
terminal motif–RBBP4 structures (34,36–38), the p.R3S mutant
peptide preferred an RBBP4 surface conformation coordinated
to Asp-198. In the wild-type peptide, Lys-5 was observed in
multiple conformations, both coordinated in a binding pocket
on the RBBP4 surface and uncoordinated and solvent exposed;
but in the p.R3S mutant, the uncoordinated solvent exposed
conformations were more frequently observed than with the
wild-type peptide (Fig. 5B). The side chain of Gln-6 was alsomore
conformationally flexible in the mutant where it assumed a
series of Ser-378-localized and Ser-378-coordinated conforma-
tions unique to the p.R3S mutant peptide. Simulation results
suggest that the p.R3S substitution induces a peptide backbone
conformational change that affects adjacent residues. In one
direction, this conformational change exposes to solvent both
the known PTM site Ser-2 (39) and the mutant Ser-3. In the other
direction, the loss of one of the three conserved ionic interac-
tions affects the coordination of Arg-4 and most prominently
Lys-5.
We examined the consequence of the BCL11B p.R3S sub-
stitution on the statistical binding free energy by calculating
the potential of mean force (PMF) from a series of overlapping
15 ns MD simulations taken along the association–dissociation
reaction coordinate of the peptide–complex. The analyses cal-
culated a G of the mutation of 1 kcal/mol (Fig. 5C) a value in
agreement with fluorescence anisotropy results (Fig. 3B), adding
confidence to the MD-based analyses above.
Craniosynostosis in mice harbouring the BCL11B p.R3S
substitution
To confirm causality of the BCL11B p.R3S substitution for
craniosynostosis and to generate a geneticmodel of the disorder,
we introduced the c.7C>A mutation into the germ line of
C57BL/6 mice using CRISPR-Cas9 (clustered, regularly inter-
spaced, short palindromic repeat/CRISPR-associated protein 9)
genome editing (40) as outlined in Figure 6 and described in the
Reagents and Techniques section.
Heterozygous,Bcl11bR3S/+ micewere born atMendelian ratios,
survived into adulthoodwithout gross anatomical abnormalities
and bred normally. However, examination of calvarial sutures by
micro-CT revealed that Bcl11bR3S/+ mice exhibited variable and
partial, bilateral osteogenic fusion of the coronal suture that
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Figure 5. MD analyses of the p.R3S substitution on interaction of BCL11B with
RBBP4–MTA1. (A) Ramachandran plots of the p.R3S substitution showing the
effects on the site of mutation and adjacent residues. The plots show the
distribution of backbone configurations from five independent simulations of
wild-type (blue) and p.R3S mutant (red) BCL11B peptides bound to RBBP4–MTA1
complex calculated fromMD simulations between 50 and 100 ns. (B) Root-mean-
square fluctuation and solvent accessible surface area of the wild-type (blue)
and p.R3S mutant (red) BCL11B peptide from MD simulations. The mean of five
independent simulations calculated between 50 and 100 ns is shown, and the
shaded regions represent the standard deviations. For wild-type Arg-3, only the
backbone atoms in commonwithmutant Ser-3 are shown. (C) PMF fromumbrella
sampling molecular dynamic simulations. Umbrella sampling simulations for
wild-type and BCL11B p.R3S amino-terminal peptides binding to RBBP4–MTA1
complex as a function of reaction coordinate (ξ ), which is the centre-of-mass
distance between the complex and peptide (illustrated in the inset). The plotted
values are the mean of 500 bootstrapped simulations from which the Gbind
was −19.5 kcal/mol for the BCL11B peptide and −18.5 kcal/mol for BCL11B p.R3S
peptide.
was accompanied by narrowing of the sagittal and lambdoid
sutures by ∼50% at P0 (compare panels A with B, D with E
and G with H of Fig. 7; Supplementary Material, Figs S1 and
S2). Other calvarial and facial sutures in the Bcl11bR3S/+ mice
were indistinguishable from those of wild-type mice (Fig. 7A–D;
Supplementary Material, Fig. S3).
Homozygous, mutant mice (Bcl11bR3S/R3S) recapitulated
perinatal lethality of Bcl11b−/− mice, due to apparent respiratory
insufficiency (26), as well as multi-suture craniosynostosis
at P0 involving the coronal (bilateral), interfrontal, sagittal,
interparietal and temporal sutures (Fig. 7C, F and I). However,
in marked contrast to Bcl11b−/− mice or those lacking BCL11B
in cells derived from neural crest (29), Bcl11bR3S/R3S mice did not
exhibit fusion of facial sutures (Fig. 7F; Supplementary Material,
Fig. S3). The sutural mesenchyme of the facial skeleton is the
most sensitive to loss of BCL11B and frequently undergoes
premature osteogenic differentiation in Bcl11b+/− heterozygotes
(29).
Discussion
This paper describes a novel, de novo mutation of BCL11B in
a patient with unilateral coronal suture craniosynostosis. The
patient suffered severe sequelae requiring three corrective surg-
eries before the age of 13 years, suggesting a significant and
progressive clinical course. The patient was negative for muta-
tions of known craniosynostosis-related genes, which together
with our previous demonstration that Bcl11b−/− mice exhibit
craniosynostosis, including of the coronal suture (29), led us
to evaluate the molecular consequences of the BCL11B p.R3S
substitution and generate a mouse model for this mutation.
BCL11B contains an amino-terminal motif shared among a
class of NuRD complex interacting transcription factors and the
p.R3S substitution replaces Arg-3 of this highly conserved motif
with serine (Fig. 1J). Crystal structures of RBBP4 in complex with
the amino-terminal fragments of FOG-1 (34), BCL11A (36) and
SALL4 (37) showed the motif residues Arg-3, Arg-4 and Lys-5
coordinated to the acidic core and surface of RBBP4 (Fig. 3A),
suggesting that the Arg-3 contributes to the ionic coordination
stabilizing its interaction with RBBP4 and closely related RBBP7.
In these structures, Arg-3 appeared to be more flexible than
the other motif invariant residues. Its electron density was not
resolved in the ZNF827–RBBP4 structure (38), and unlike Arg-
4 and Lys-5, the side-chain electron densities of Arg-3 fit to
four slightly different coordination positions among the three
resolved structures. Substitutions at Arg-3 are also more sensi-
tive to context than other motif invariant residues. Site-directed
mutagenesis of FOG-1 showed that Arg-4 and Lys-5 were crit-
ical for both high-affinity interaction with NuRD complex and
transcriptional repressive activity. In contrast,mutation of Arg-3
selectively affected the affinity of FOG-1 for subtypes of NuRD
complexes, contributing more to the stability of MTA2–NuRD
than toMTA1–NuRD complexes (41).Moreover,mutation of Arg-3
only partly impaired FOG-1-mediated transcriptional repressive
activity (41). However, Arg-3, Arg-4 and Lys-5 contribute equally
to FOG-2-mediated transcriptional repression, suggesting that
the individual residues of these motifs may exhibit a degree
of contextual specificity (42). We found the p.R3S substitution
in BCL11B eliminated detectable interaction with NuRD com-
plex, also with the RBBP4/7-containing PRC2 complex, without
affecting its interaction with SIRT1 (Fig. 2B and C), an interaction
previously shown to involve an internal BCL11B domain inde-
pendent of the amino terminus (33). BCL11B harbours multiple
protein–protein interactions domains (33,43–46), and the present
results suggest that the effect of the p.R3S substitution may be
limited to a subset of interactions that depend on the amino-
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Figure 6. Strategy for generating Bcl11bR3S mice. (A) Mouse Bcl11b genomic sequence around the translation start site (boxed) with CRISPR-Cas9 guide RNA (gRNA) target
site and protospacer adjacent motif (underlined) shown. The 127 nucleotides sequence used in the donor oligonucleotide for homology directed repair is shaded. The
donor sequence included two mismatches to the genomic sequence to introduce a SacII site for screening purposes (shown in blue) and the c.7C>A; p.R3S mutation
(shown in red). (B) DNA sequence from an ES clone with a heterozygous SacII site and homozygous c.7C>Amutation (red arrow, top). Germline transmission of c.7C>A
with and without the SacII site (below). The translation start codon is boxed.
terminal motif of BCL11B with RBBP4/7-containing transcrip-
tional regulatory complexes.
We examined the interaction of BCL11B and BCL11B p.R3S
peptides with a subassembly of the NuRD complex composed
of RBBP4 and a large fragment of MTA1. Our in vitro binding data
demonstrated that the p.R3S peptide bound to the RBBP4–MTA1
with an affinity that was nearly an order of magnitude less than
that of the corresponding wild-type peptide (Fig. 3B). Further-
more, results of MD simulations suggested that the p.R3S sub-
stitution additionally induced a conformational change in the
BCL11B peptide, increased its disorder, negatively affected bind-
ing stability and potentially increased its potential for ectopic
PTM (Fig. 5A and B).
Other interactions within the NuRD–BCL11B complex could
positively or negatively impact interaction of wild-type BCL11B
and/or BCL11B p.R3S proteins with the RBBP4–MTA1 complex.
Based on previous structural studies of this subassembly (35)
and a report that BCL11B interacts with MTA1 and MTA2 (45),
it is conceivable that an MTA protein bound to RBBP4 could
contribute to the stability of BCL11B interaction with RBBP4.
Indeed, modelling results (Fig. 4) suggest that MTA1 region 466–
468 may interact with Leu-12 and Ser-13 of BCL11B to stabilize
the interaction of the latter with the holo-NuRD complex in
the metazoan nucleus. Unfortunately, the available structural
data does not include regions of MTA1/2 that could interact
with both RBBP4/7 and the amino-terminal motif containing the
substitution site.
The amino termini of BCL11B and related transcription fac-
tors share sequence (Fig. 1J) and structural (Fig. 8) homologywith
the amino-terminal tail of histone H3 when bound to RBBP4/7
factors. One consequence of the BCL11B p.R3S substitution is to
expose both the mutant Ser-3 and the adjacent Ser-2 residues
to solvent, similar to the position of Thr-3 histone H3 when
bound to RBBP4/7 (Fig. 8). In histone H3, Arg-2 and Lys-4 are both
methylated and Thr-3 is phosphorylated. With the exception
of Ser-2 phosphorylation in transiently transfected cells (39),
similar PTMs of the amino tail of BCL11B are unknown, but it is
conceivable that the p.R3S substitution renders the amino tail of
BCL11B susceptible to other, histone-like PTMs, such as ectopic
phosphorylation of the mutant p.R3S site.
Disruption of the interaction of BCL11B with RBBP4 and
RBBP7 could have profound effects on the transcriptional
regulatory activity of BCL11B. BCL11B, a sequence-specific
transcription factor, presumably recruits the RBBP4/7-containing
complexes to specific genetic loci that are transcriptionally
regulated by BCL11B. The reduced affinity of BCL11B p.R3S
for RBBP4/7 could greatly compromise BCL11B-dependent
recruitment of RBBP4/7-containing transcriptional regulatory
complexes to chromatin, resulting in targeted dysregulation of
gene expression.Moreover, the sequential nature of recruitment
of RBBP4/7-containing transcriptional complexes to target
chromatin may serve to amplify the dampened affinity of
BCL11B p.R3S for RBBP4/7. For example, BCL11B-mediated
repression of a subset of genes may involve sequential
NuRD-mediated deacetylation of H3K27ac followed by PRC2-
dependent methylation of H3K27, generating a transcriptionally
non-permissive environment underpinned by the H3K27me3
modification (47–49). H3K27me3 locks down a transcriptionally
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Figure 7. Craniosynostosis in mice harbouring p.R3S substitution. Superior (A–C), lateral (D–F) and sagittal sectional (G–I) views of micro-CT scans of wild-type control,
Bcl11bR3S/+ and Bcl11bR3S/R3S in P0 mice skulls. Arrowheads indicate increased mineralization and reduced anterior fontanel (af) and affected coronal (c), interfrontal
(if), lambdoid (lb), premaxillary-maxillary (pm), sagittal (s) and temporal (t) sutures. Calvarial interparietal (IP), frontal (F), nasal (N) and parietal (P) bones are indicated
in the figure, and the blue line indicates dental occlusion. Scale bar, 1 mm.
Figure 8. Common structural motif shared with histone H3 tail. The structural
alignment of FOG-1 (pink) bound to RBBP4 (blue; PDB ID: 2XU7) (34) and histone
H3 (green) bound to RBBP4/7Drosophilahomolog (tan; PDB ID: 2YBA) (71) is shown.
BCL11B shares an identical sequence with FOG-1 (structure shown) through Gln-
6 (see Fig. 1J).
repressive state that is physiologically critical in development,
cellular differentiation and inactivation of the X chromosome
(50–52). As BCL11B-mediated recruitment of both NuRD and
PRC2 to this hypothetical locus presumably requires the
sequential and binary interaction of BCL11B with RBBP4 (or
RBBP7), the p.R3S substitution reported herein could have a
multiplicative effect on the transcriptional outcome at this locus.
This phenomenon may explain, at least partially, strong ectopic
expression—or de-repression—of Runx2 and/or Fgfr2cwithin the
non-osteogenic mesenchyme of the coronal suture in Bcl11b−/−
mice at E16.5, followed by ossification of this suture by E18.5 (29).
We generated a mouse model for the BCL11B p.R3S sub-
stitution, and this single amino acid change recapitulated
coronal suture craniosynostosis in both the heterozygous
and homozygous backgrounds. However, craniosynostosis in
Bcl11bR3S/+ mice was much less severe and more highly variable
than that observed in homozygous Bcl11bR3S/R3S mice. These
findings demonstrate that the BCL11B p.R3S substitution is
causally related to the craniosynostosis seen in our patient.
Neither Bcl11bR3S/+ nor Bcl11bR3S/R3S mice exhibited synostosis
of sutures within the facial skeleton. This finding is surpris-
ing because we have previously found that facial sutures are
even more sensitive to BCL11B dosage than those of the cra-
nial skeleton (29), suggesting that the transcriptional regulatory
complexes that BCL11B may work through to control suture
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patency in the facial skeleton are different from those required
by the transcription factor to regulate cranial suture patency.
Consistent with this speculation, our co-immunoprecipitation
studies indicated that the p.R3S substitution selectively affected
interaction of BCL11B with RBBP4- and RBBP7-containing com-
plexes (NuRD and PRC2), but did not affect interaction with
complexes that require other regions of BCL11B for interaction,
e.g. the class III HDAC SIRT1 (33). Thus, the Bcl11bR3S/R3S mouse
model generated herein may provide a means to dissect the
mechanistic basis of BCL11B action in vivo and in several other
developmental systems in which the transcription factor plays a
critical role.
Recent reports (14,15) have described 11 monoallelic variants
at the BCL11B locus that were linked to craniofacial dysmor-
phisms, neurodevelopmental pathologies, intellectual disabili-
ties, dental anomalies and dermal defects. To date, only one of
these, a p.N441K substitution in one of the zinc finger domains
of BCL11B, has been investigatedmechanistically and is reported
to impact binding of BCL11B to known regulatory regions of the
genome, alter the specificity of DNA binding by BCL11B and
possibly generate a dominant-negative form of the protein (14).
Unlike the patients who have multiple developmental anoma-
lies, the patient with craniosynostosis described herein was oth-
erwise healthy and did not present with any extra-craniofacial
pathologies (14,15). In fact, the patient is now 19 years old and
is continuing to undergo his formal education. Thus, the p.R3S
substitution did not have a global effect on BCL11B function in
this patient, suggesting that this mutation most likely affected
the action of BCL11B primarily in the suturalmesenchyme. It will
be of interest to examine the function of BCL11B p.R3S in other
developmental systems, such as in the thymocyte, neuronal,
skin and tooth lineages.
We hypothesize that the p.R3S substitution results in at least
a partial or context-specific loss of BCL11B function, owing to
restricted recruitment of NuRD and/or the RBB4/7-containing
PRC2 complexes to BCL11B target loci, as described above.
However, we cannot rule out a contribution to the phenotype
through a gain of BCL11B function, in combination with the loss-
of-function effects, in a promoter context-dependent manner.
More broadly, mutations that eliminate any of the basic charges
on Arg-3, Arg-4 or Lys-5, in BCL11B or in other amino-terminal
motif-containing factors, are likely to disrupt interactions
with RBBP4/7-containing NuRD and PRC2 complexes. There
are two other reported variants affecting the charge on these
residues beyond BCL11B p.R3S, namely SALL2 p.R3P and ZNF821
p.R4W (53), but the clinical significance of either substitution is
unknown.
In conclusion, we identified a novel mutation in BCL11B
associated with coronal suture synostosis, confirmed this asso-
ciation using a newly created mouse model and demonstrated
that interaction of BCL11B with the transcriptional machinery
was partially disrupted. This mouse model should be useful in
dissecting the mechanistic basis for the role of BCL11B in main-
tenance of sutural patency, as well as in other organ systems in
which BCL11B plays a critical developmental role.
Materials and Methods
Whole-genome sequencing
Ethical approval was given for WGS by the board of the Medical
Ethical Committee Rotterdam (MEC-2012-140). Informed consent
was received from the proband and parents.
WGS was performed on trio DNA by Complete Genomics
(Mountain View, CA, USA), as described by Drmanac et al. (30).
Data were analysed using CGA Tools version 1.6.0.43. A de novo
disease model was tested, using the ‘calldiff script’ (Python
script kindly provided by Complete Genomics) as described by
Gilissen et al. (31). Prioritization of variants was based on the
minimal somatic score and manual curation of the variants
(Supplementary Material, Table S1). Confirmation of the BCL11B
de novo variant was carried out by dideoxy sequencing. The
BCL11B p.R3S variant has been deposited in the Leiden Open
Variation Database (https://www.lovd.nl/BCL11B).
Sequence analysis of BCL11B in craniosynostosis
The clinical study was approved by Oxfordshire Research Ethics
Committee B (reference C02.143) and Riverside Research Ethics
Committee (reference 09/H0706/20). Written informed consent
to obtain samples for genetics research was obtained from each
child’s parent or guardian. DNAwas extracted fromwhole blood.
BCL11B was resequenced in 382 craniosynostosis probands
negative formutations in known craniosynostosis-related genes.
Primer sequences, conditions used and bioinformatics analyses
are included in Supplementary Material, Table S3. An additional
115 patients were screened for variants in the first exon of
BCL11B by dideoxy sequencing (using standard protocols) or
by targeted resequencing (using the primers for BCL11B-Ex1;
Supplementary Material, Table S3).
Reagents and techniques
Constructs. The BCL11B construct used herein has been
described (54). BCL11B p.R3S was constructed from the parental
plasmid using a mutagenic primer and the Q5 Site-Directed
Mutagenesis Kit from New England Biolabs (NEB E0554S). The
integrity of the entire open-reading frame of BCL11Bwas verified
by dideoxy sequencing.
Generation of mutant mice. Mouse embryonic stem (ES) cells
(E14Tg2aIV, 129/Ola) were transfected with pX458 (Addgene
48138) (40) containing a guide sequence targeting a region near
the Bcl11b translation start site (5′-CCGCAAACAGGGCAACCCGC-
3′) and an oligonucleotide donor for homology directed
repair and introduction of the c.7C>A mutation (5′- gcg-
gcggcggcggctcagaccccctccccggcccgcatctgtgcagctttccgggcgatgcca
gaatagatgccgGggcaatgtccAgccgcaaacagggcaacccgcagcacttgtcccaga
ggga-3′; uppercase G indicates site of introduction of a SacII
restriction site for screening; the translation start site atg is in
boldface; uppercase A denotes the mutation base). Briefly, ES
cells were seeded onto gelatin-coated 6-well plates at 3 × 105
cells per well 1 day before transfection with 3.3 μg plasmid,
10 μl of 10 μm donor complexed with 20 μl Fugene HD (Promega)
oligonucleotide in a total volume of 100 μl made up with serum
free medium. After 24 h, cells were sorted for green fluorescent
protein-positive cells using fluorescence-activated cell sorting in
a 96-well format. A homozygous c.7C>A ES clone was identified
(containing a heterozygous SacII site), and karyotyping was
injected into blastocysts (C57BL/6) for chimera generation.
Several chimeric mice were produced, and the mutant allele
was successfully transmitted through the germline (with and
without the SacII site).
Specimen preparation and scanning. Skulls from P0 mice were
collected and stored in 70% ethanol prior to scanning. Skulls
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were scanned using a Scanco μCT40 scanner (Scanco Medical
AG, Basserdorf, Switzerland) at 12 μm voxel size, 55 kVp X-ray
voltage, 145 μA intensity, with a 200 ms integration time as
previously described (29). Stacks of imageswere also individually
analysed in MicroView (version 2.5.0; GE Healthcare Biosciences,
London, Ontario, Canada) to extract sagittal sections of the coro-
nal and lambdoid sutures in all genotypes of mice. Mouse work
was performed in accordance with UK Home Office regulations
under approved project licences and the Oregon State University
Institutional Animal Care and Use Committee.
Co-immunoprecipitations. HEK293T cells were transfected with
vectors encoding FLAG-BCL11B (54), FLAG-BCL11B p.R3S or Myc-
SIRT1 using the calcium phosphate method. Transfected cells
were harvested in ice-cold phosphate-buffered saline (PBS) 48 h
after transfection. Cell suspensions were centrifuged at 2000g
for 5 min, followed by lysis under native conditions in buffer
containing 20 mm HEPES, pH 7.4, 250 mm NaCl, 2 mm EDTA, 10%
glycerol, 0.5% NP-40, 0.1 mm PMSF, 1 μg/mL pepstatin A, 5 μg/mL
leupeptin, 10 μm E64, 25 mm NaF, 5 mm Na2P2O4 and 10 mm N-
ethylmaleimide. Cells were incubated on ice for 30 min with
vortexing every 5 min, followed by sonication on ice to complete
lysis and shear DNA. The lysate was cleared by centrifugation,
and BCL11B was immunoprecipitated from native extracts
with anti-FLAG antibody (Sigma F4042), as previously described
(54). SDS-PAGE immunoblot analyses used rat monoclonal
anti-BCL11B (Abcam ab18465, 0.5 μg/ml) and the following
rabbit primary antibodies: anti-MTA2 (Bethyl Laboratories A300-
395A,1:5000 dilution), anti-HDAC2 (Bethyl A300-705A, 1:5000
dilution), anti-EZH2 (EMD-Millipore 07–689, 1:2000 dilution)
and anti-Myc (Cell Signaling 2278, 1:1000 dilution to detect
Myc-SIRT1), followed by IRDye680LT-conjugated anti-rat and
IRDye800CW-conjugated anti-rabbit secondary antibodies (LI-
COR Biosystems, Lincoln, NB, USA) used in combination.
Fluorescent signal was recorded on an Odyssey dual-channel
near-infrared imager (LI-COR) and analysed with manufacturer-
supplied software (Image Studio, version 2.1).
Immunocytochemistry. HEK293T cells were grown on 0.1%
gelatin-coated glass coverslips in 24-well plates seeded at 25 000
cells/well for 24 h prior to transfection with vectors encoding
FLAG-BCL11B or FLAG-BCL11B p.R3S. Forty-eight hours after
transfection, cells were washed twice with PBS, fixed in 4%
paraformaldehyde in PBS for 10 min at room temperature,
permeabilizedwith 0.3%TritonX-100/PBS for 10min andwashed
twice with 0.1% Tween/PBS. The fixed and permeabilized cells
were then prepared for immunocytochemistry by blocking
for 1 h in 10% foetal bovine serum (FBS) in PBS, incubating
for 4 h with rat anti-BCL11B monoclonal antibody (Abcam
ab18465, 0.25 μg/ml) in 10% FBS/PBS, then incubating for
1.5 h with an anti-rat Cy3-conjugated secondary antibody
(Jackson ImmunoResearch Laboratories, 1:500 dilution), followed
by a final incubation in 10 μg/ml DAPI in PBS for 10 min.
Cells were washed twice with 0.1% Tween/PBS between each
immunocytochemistry step, and all incubations were conducted
at room temperature. Cells were then washed twice with
deionized water, followed by step-wise dehydration with
70% ethanol, 100% ethanol and xylene. Coverslips were then
mounted on glass slides with DPX (VWR), dried overnight and
stored at 4◦C in the dark. Fluoromicrographs were obtained
using a Zeiss microscope with appropriate filters and a 63×
oil-immersion objective. Colour images were digitally overlaid
using Zeiss AxioVs40 software, version 4.8.2.0.
Fluorescence anisotropy. Steady-state fluorescence anisotropy
of fluorescein-labelled wild-type BCL11B and BCL11B p.R3S
amino-terminal peptides and unlabelled RBBP4–MTA1 complex
were recorded in black 96-well plates (Corning) at room tem-
perature using a Victor X5 plate reader (Perkin Elmer). Synthetic
BCL11B peptides (residues 1–15) were carboxy-terminal labelled
with 5-carboxyfluorescein (5-FAM) and were purchased from
Cambridge Research Biochemicals (Billingham, UK), and the
complex of full-length RBBP4 and residues 464–546 of MTA1
were prepared as previously described (35). Measurements were
conducted in buffer containing 50 mm Tris, pH 7.5, 150 mm NaCl,
0.15 mg/mL BSA and 0.03% Tween-20. Fluorescence was excited
at 480 nm and monitored at 535 nm. For each concentration of
RBBP4–MTA1, anisotropy, A,was calculated according to
A = I‖ − I⊥
I‖ + 2I⊥ , [Eq. 1]
where I‖ is the fluorescence intensity measured in the parallel
plane and I⊥ is the fluorescence intensity measured in the
perpendicular plane. Anisotropy measurements were fit to the
following equation:
A = b −
√
b2 − 4 [L]Amax
2
, [Eq. 2]
where [L] is the total concentration of RBBP4–MTA1 complex,
Amax is the anisotropy of the complex bound fluorescein-labelled
peptide, K is the dissociation constant of the peptide and
b = Amax + K + [L].
Molecular modelling. MD simulations of the conserved amino-
terminal tails of wild-type BCL11B and BCL11B p.R3S bound to
the RBBP4–MTA1 complex were based on the high-resolution
structures of FOG-1 peptide bound to RBBP4 (PDB ID: 2XU7) (34)
and the RBBP4–MTA1 complex using PDB IDs 4PBY (55) and 5FXY
(35). Modeller version 9.17 (56,57) and SCWRL4 (58) were used to
generate initial simulation models consisting of residues 1–15 of
BCL11B and BCL11B p.R3S, 8–411 of RBBP4 and 464–546 of MTA1.
MD simulations used the GROMACS software package, version
2016 (59) and were conducted in explicit solvent of 0.15 m NaCl
in TIP3P model of water, neutralized with additional sodium
ions and parameterized with the CHARMM36m all-atom force
field (60), which was chosen to model the inherently disor-
dered BCL11B peptides. The LINCS algorithm (61) was used to
constrain all bonds; short-range Coulombic and van der Waals
non-bonded interactions were cut off at 1.2 nm, and long-range
electrostatics were calculated according to the particle-mesh
Ewald algorithm (62). Periodic boundary conditions were applied
to all dimensions.
The modelled peptide–complex systems were equilibrated
to simulation conditions following steepest descent energy
minimization in two steps with positional restraints placed on
the protein heavy atoms. First, the temperature was stabilized
under a canonical constant volume (NVT) ensemble for 100 ps.
Subsequently,pressurewas stabilized under isothermal–isobaric
ensemble (NPT) for 200 ps. Protein and solvent were coupled
to separate temperature baths and maintained with the
Nosé–Hoover thermostat (63,64) at 310 K, and pressure was
maintained at 1 bar with the Parrinello–Rahman barostat (65).
Following equilibration, unrestrained MD simulations were
conducted for 100 ns to generate initial configurations for
steeredmolecular dynamics (SMD) simulations (66). During each
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SMD simulation, the RBBP4 centre ofmass was fixed and BCL11B
peptides were pulled along the axis orthogonal to the peptide
binding site by a force attached to the peptide centre of mass
with a harmonic spring constant of 1000 kJ/mol/nm2 at a rate
of 0.001 nm/ps for 3.5 ns. Starting configurations for umbrella
sampling equilibrium MD were extracted from these SMD
trajectories to provide a distribution of overlapping sampling
windows along the SMD reaction coordinate. Each extracted
configurationwas then re-equilibratedwith positional restraints
placed on protein-heavy atoms under NPT ensemble for 100 ps
prior to 15 ns of unrestrained MD simulation. The weighted
histogramanalysismethod (67,68) was used to calculate the one-
dimensional PMF as a function of centre-of-mass separation.
Supplementary Material
Supplementary Material is available at HMG online.
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